Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

HIV-associated lymphomas ; ВИЧ-ассоциированные лимфомы

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • بيانات النشر:
      Bashkir State Medical University
    • الموضوع:
      2023
    • Collection:
      Creative surgery and oncology (E-Journal) / Креативная хирургия и онкология
    • نبذة مختصرة :
      A steady worldwide increase in the number of people living with HIV (PLHIV) and diagnostic methods requires a separate review of patient-specific nosologies, including lymphoproliferative diseases, some of which are directly associated with the virus due to its oncogenic effect and those that do not relate directly to HIV but introduce nuances to diagnostic and therapeutic approaches when a patient is HIV-positive. Towards this, the paper generally reviews lymphomas in PLHIV, presents the WHO classification of HIV-associated lymphomas, describes a contemporary view of the known mechanisms of pathogenesis, including the role of opportunistic infections, and general principles of diagnostic and therapeutic tactics, provides recommendations on modifying the doses of chemotherapy correlated with the immune status and on preventing CNS involvement. Specific types of lymphoma (Burkitt’s lymphoma, diff use large B-cell lymphoma) are considered separately, including those most frequently associated with patients living with HIV (primary effusion lymphoma, plasmablastic lymphoma, primary central nervous system lymphoma), but rare in the uninfected population. ; Стабильный рост в мире числа людей, живущих с вирусом иммунодефицита человека (ЛЖВИЧ), и методов диагностики требует отдельного разбора специфических для указанной категории пациентов нозологий, в том числе лимфопролиферативных заболеваний, развитие части которых непосредственно ассоциировано с вирусом в связи с его онкогенным действием, и тех, что не относятся к непосредственно к ВИЧ-связанным, но вносящих нюансы в диагностические и терапевтические подходы при наличии у пациента ВИЧ-положительного статуса. С этой целью в статье рассмотрены лимфомы у ЛЖВИЧ, приведена классификация ВИЧ-ассоциированных лимфом Всемирной организации здравоохранения (ВОЗ), описаны современные представления об известных механизмах патогенеза, в том числе о роли оппортунистических инфекций, и общие принципы диагностической и терапевтической тактики, приведены рекомендации по модификации ...
    • File Description:
      application/pdf
    • Relation:
      https://www.surgonco.ru/jour/article/view/739/524; Lamers S.L., Fogel G.B., Huysentruyt L.C., McGrath M.S. HIV-1 nef protein visits B-cells via macrophage nanotubes: a mechanism for AIDS-related lymphoma pathogenesis? Curr HIV Res. 2010;8(8):638–40. DOI:10.2174/157016210794088209; Noy A. HIV Lymphoma and Burkitts Lymphoma. Cancer J. 2020;26(3):260–8. DOI:10.1097/PPO.0000000000000448; Siangphoe U., Archer K.J., Nguyen C., Lee K.R. Associations of antiretroviral therapy and comorbidities with neurocognitive outcomes in HIV-1-infected patients. AIDS. 2020;34(6):893–902. DOI:10.1097/QAD.0000000000002491; Wang Z., Zhang R., Liu L., Shen Y., Chen J., Qi T., et al. Incidence and spectrum of infections among HIV/AIDS patients with lymphoma during chemotherapy. J Infect Chemother. 2021;27(10):1459–64. DOI:10.1016/j.jiac.2021.06.012; Khan A., Brahim A., Ruiz M., Nagovski N. Relapsed/refractory Burkitt lymphoma and HIV infection. Int J STD AIDS. 2018;29(7):695–703. DOI:10.1177/0956462417748239; Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, Bohlius J., Schmidlin K., Costagliola D., Fätkenheuer G., et al. Incidence and risk factors of HIV-related nonHodgkin’s lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antivir Ther. 2009;14(8):1065–74. DOI:10.3851/IMP1462; Borges Á.H., Neuhaus J., Sharma S., Neaton J.D., Henry K., Anagnostou O., et al. The effect of interrupted/deferred antiretroviral therapy on disease risk: a SMART and START combined analysis. J Infect Dis. 2019;219(2):254–63. DOI:10.1093/infdis/jiy442; Shepherd L., Borges Á.H., Harvey R., Bower M., Grulich A., Silverberg M., et al. The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people. HIV Med. 2018;19(2):90–101. DOI:10.1111/hiv.12546; Breen E.C., Hussain S.K., Magpantay L., Jacobson L.P., Detels R., Rabkin C.S., et al. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol Biomarkers Prev. 2011;20(7):1303–14. DOI:10.1158/1055-9965.EPI-11-0037; Peckham-Gregory E.C., Thapa D.R., Martinson J., Duggal P., Penugonda S., Bream J.H., et al. MicroRNA-related polymorphisms and non-Hodgkin lymphoma susceptibility in the Multicenter AIDS Cohort Study. Cancer Epidemiol. 2016;45:47–57. DOI:10.1016/j.canep.2016.09.007; Martorelli D., Muraro E., Mastorci K., Dal Col J., Faè D.A., Furlan C., et al. A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: implications for EBV-driven lymphomagenesis in the HIV setting. Int J Cancer. 2015;137(6):1374–85. DOI:10.1002/ijc.29494; Sall F.B., El Amine R., Markozashvili D., Tsfasman T., Oksenhendler E., Lipinski M., et al. HIV-1 Tat protein induces aberrant activation of AICDA in human B-lymphocytes from peripheral blood. J Cell Physiol. 2019 Jan 31. DOI:10.1002/jcp.28219; Germini D., Tsfasman T., Klibi M., El-Amine R., Pichugin A., Iarovaia O.V., et al. HIV Tat induces a prolonged MYC relocalization next to IGH in circulating B-cells. Leukemia. 2017;31(11):2515–22. DOI:10.1038/leu.2017.106; El-Amine R., Germini D., Zakharova V.V., Tsfasman T., Sheval E.V., Louzada R.A.N., et al. HIV-1 Tat protein induces DNA damage in human peripheral blood B-lymphocytes via mitochondrial ROS production. Redox Biol. 2018;15:97–108. DOI:10.1016/j.redox.2017.11.024; Isaguliants M., Bayurova E., Avdoshina D., Kondrashova A., Chiodi F., Palefsky J.M. Oncogenic Effects of HIV-1 Proteins, Mechanisms Behind. Cancers (Basel). 2021;13(2):305. DOI:10.3390/cancers13020305; Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382(6593):722–5. DOI:10.1038/382722a0; Thorball C.W., Oudot-Mellakh T., Ehsan N., Hammer C., Santoni F.A., Niay J., et al. Genetic variation near CXCL12 is associated with susceptibility to HIV-related non-Hodgkin lymphoma. Haematologica. 2021;106(8):2233–41. DOI:10.3324/haematol.2020.247023; Besson C., Goubar A., Gabarre J., Rozenbaum W., Pialoux G., Châtelet F.P., et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood. 2001;98(8):2339–44. DOI:10.1182/blood.v98.8.2339; Barta S.K., Xue X., Wang D., Tamari R., Lee J.Y., Mounier N., et al. Treatment factors affecting outcomes in HIV-associated nonHodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122(19):3251–62. DOI:10.1182/blood-2013-04-498964; Schmitz N., Zeynalova S., Nickelsen M., Kansara R., Villa D., Sehn L.H., et al. CNS International Prognostic Index: A risk model for CNS relapse in patients with diffuse large B-Cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34(26):3150–6. DOI:10.1200/ JCO.2015.65.6520; B-cell Lymphomas. — National Comprehensive Cancer Network; [cited 2021 Oct 23]. Available from: www.nccn.org/guidelines/guidelines-detail?category=1&id=1480; Sparano J.A., Lee J.Y., Kaplan L.D., Ramos J.C., Ambinder R.F., Wachsman W., et al. Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin’s lymphoma. Haematologica. 2021;106(3):730–5. DOI:10.3324/haematol.2019.243386; Lyman G.H. Evaluation and regulation of oncology drug approval: finding the right balance. JAMA Oncol. 2016;2(6):728–9. DOI:10.1001/jamaoncol.2015.6477; Barta S.K., Lee J.Y., Kaplan L.D., Noy A., Sparano J.A. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated nonHodgkin lymphoma. Cancer. 2012;118(16):3977–83. DOI:10.1002/cncr.26723; Boué F., Gabarre J., Gisselbrecht C., Reynes J., Cheret A., Bonnet F., et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin’s lymphoma. J Clin Oncol. 2006;24(25):4123–8. DOI:10.1200/JCO.2005.05.4684; Habbous S., Guo H., Beca J., Dai W.F., Isaranuwatchai W., Cheung M., et al. The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B-cell lymphoma. Cancer Med. 2020;9(19):7072–82. DOI:10.1002/cam4.3362; Noy A., Lee J.Y., Cesarman E., Ambinder R., Baiocchi R., Reid E., et al. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood. 2015;126(2):160–6. DOI:10.1182/blood-2015-01-623900; Kassam S., Bower M., Lee S.M., de Vos J., Fields P., Gandhi S., et al. A retrospective, multi-center analysis of treatment intensification for human immunodeficiency virus-positive patients with high-risk diffuse large B-cell lymphoma. Leuk Lymphoma. 2013;54(9):1921–7. DOI:10.3109/10428194.2012.754024; Barnes J.A., Lacasce A.S., Feng Y., Toomey C.E., Neuberg D., Michaelson J.S., et al. Evaluation of the addition of rituximab to CODOX-M/ IVAC for Burkitt’s lymphoma: a retrospective analysis. Ann Oncol. 2011;22(8):1859–64. DOI:10.1093/annonc/mdq677; Zhu K.Y., Song K.W., Connors J.M., Leitch H., Barnett M.J., Ramadan K., et al. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab. Br J Haematol. 2018;181(6):782–90. DOI:10.1111/bjh.15262; Chen M., Wang Z., Fang X., Yao Y., Ren Q., Chen Z., et al. Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma. Cancer Biol Med. 2021;18(3):833–40. DOI:10.20892/j.issn.2095-3941.2020.0314; Thomas D.A., Faderl S., O’Brien S., Bueso-Ramos C., Cortes J., Garcia-Manero G., et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106(7):1569–80. DOI:10.1002/cncr.21776; Holte H., Leppä S., Björkholm M., Fluge O., Jyrkkiö S., Delabie J., et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/ follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol. 2013;24(5):1385–92. DOI:10.1093/annonc/mds621; Gupta N.K., Nolan A., Omuro A., Reid E.G., Wang C.C., Mannis G., et al. Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro Oncol. 2017;19(1):99–108. DOI:10.1093/neuonc/now155; Gijs P.J., Clerc O. Long-term remission of AIDS-related primary central nervous system lymphoma in a patient under antiretroviral therapy: a case report and review of the literature. AIDS Res Ther. 2021;18(1):76. DOI:10.1186/s12981-021-00403-6; Jin M., Yang Z., Li J., Liu X., Wu Z. Factors Influencing Survival Status of HIV/AIDS after HAART in Huzhou City, Eastern China. Can J Infect Dis Med Microbiol. 2022;2022:2787731. DOI:10.1155/2022/2787731; Epeldegui M., Martínez-Maza O. Immune ACTIVATION: CONTRIBUTION to AIDS-associated Non-Hodgkin lymphoma. For Immunopathol Dis Therap. 2015;6(1–2):79–90. DOI:10.1615/ForumImmunDisTher.2016014177; Nagai H., Odawara T., Ajisawa A., Tanuma J., Hagiwara S., Watanabe T., et al. Whole brain radiation alone produces favourable outcomes for AIDS-related primary central nervous system lymphoma in the HAART era. Eur J Haematol. 2010;84(6):499–505. DOI:10.1111/j.1600-0609.2010.01424.x; Brandsma D., Bromberg J.E.C. Primary CNS lymphoma in HIV infection. Handb Clin Neurol. 2018;152:177–86. DOI:10.1016/B978-0-444-63849-6.00014-1; Wong, A.B., Tseng A.D. HIV oncology handbook. Antiretroviral interactions with chemotherapy regimens. Toronto; 2014.; Major A., Smith S.M. DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose? Clin Adv Hematol Oncol. 2021;19(11):698–709. PMID: 34807015; Mead G.M., Barrans S.L., Qian W., Walewski J., Radford J.A., Wolf M., et al. A prospective clinicopathologic study of dose-modified CODOXM/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008;112(6):2248–60. DOI:10.1182/blood-2008-03-145128; https://www.surgonco.ru/jour/article/view/739
    • الرقم المعرف:
      10.24060/2076-3093-2022-12-4-320-327
    • الدخول الالكتروني :
      https://www.surgonco.ru/jour/article/view/739
      https://doi.org/10.24060/2076-3093-2022-12-4-320-327
    • Rights:
      Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). ; Авторы, публикующие статью в данном журнале, соглашаются со следующим:Авторы сохраняют за собой авторские права на работу и предоставляют журналу право первой публикации работы на условиях лицензии Creative Commons Attribution License, которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в этом журнале.Авторы сохраняют право заключать отдельные контрактные договорённости, касающиеся не-эксклюзивного распространения версии работы в опубликованном здесь виде (например, размещение ее в институтском хранилище, публикацию в книге), со ссылкой на ее оригинальную публикацию в этом журнале.Авторы имеют право размещать их работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу (См. The Effect of Open Access).
    • الرقم المعرف:
      edsbas.7B05F3A5